Roivant Sciences (ROIV) Insider LP Sells $437K of Stock

Qvt Financial's Recent Share Sale

On June 30, Qvt Financial LP sold 12,380 shares of Roivant Sciences Ltd. (NasdaqGS: ROIV) for about $436,766. The average sale price was $35.28 per share, which is slightly below the last closing price of $39.77. This sale adds to the recent activity among insiders at Roivant.

Insider Buying and Selling at Roivant Sciences Ltd.

This is not the first significant insider move at Roivant. Just days earlier, on June 25, Roivant's President & CIO, Mayukh Sukhatme, sold 500,000 shares valued at $17.07 million. Sukhatme had also exercised options on the same day for another 500,000 shares at a much lower price of $3.85. Additionally, Eric Venker, who is both President of Roivant and CEO of Immunovant, sold 200,000 shares on June 24 but also acquired 200,000 shares on the same day for $770,000. CFO Richard Pulik and Chief Accounting Officer Jennifer Humes also sold shares on June 20, indicating active trading within the company's leadership.

Recent Analyst Ratings

Analysts have recently been active in their coverage of Roivant. On September 17, Stifel initiated coverage with a Buy rating and a target price of $51. On September 9, TD Cowen maintained their Buy rating but raised their price target to $55. Guggenheim also maintains a Buy rating, with a current price target of $46, up from $42. The overall consensus among 12 analysts is a strong buy with a mean target price of $47.79.

How Roivant Sciences Ltd. Stock Has Traded

Roivant shares are currently trading at $35.39, which is down from a recent close of $39.77. This puts the stock well below its 52-week high of $42.50 and above its low of $14.50. The stock is trading just above its 50-day moving average of $36.26, suggesting some resistance in price movement. With analysts maintaining a strong buy rating, it will be interesting to see if the stock can regain upward momentum.

Recent Earnings

In its latest quarter, Roivant reported a revenue of $7.53 million but faced challenges with negative revenue growth of 33.5%. The company also has a negative return on equity (ROE) of -8.5% and an EPS of -0.47. Investors will be looking for improvements when the company announces its next earnings on November 9.

What Roivant Sciences Ltd. Does

Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company with a focus on developing medicines and technologies for various health conditions. The company is advancing several clinical candidates, including treatments for autoimmune diseases and pulmonary hypertension. Given the recent insider sales, market watchers may be curious about future developments and performance in the months ahead.

What's Next for Roivant?

Looking ahead, investors will want to keep an eye on Roivant's upcoming earnings report on November 9, as well as any further insider transactions. The recent trading activities by key executives could provide additional insights into the company's direction and outlook. As a reminder, this insider sale reflects the position as of June 30 and may not represent current holdings.